FUJIFILM Medical Systems U.S.A., Inc. announced it will showcase its portfolio of Synapse® Enterprise Imaging solutions at the 2021 Society for Imaging Informatics in Medicine (SIIM) Conference taking place May 24- 27.
Inspirata and Fujifilm UK Partnership Generates NHS Success with One Dorset Pathology Network Digital Pathology Engagement
May 19, 2021 04:00 ET | Source: Inspirata, Inc. Inspirata, Inc. Tampa, Florida, UNITED STATES
London, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) Cancer informatics and digital pathology provider Inspirata announced today that University Hospitals Dorset NHS Foundation Trust will commence an implementation of its Dynamyx™ digital pathology software (“Dynamyx”), as part of an agreement struck between enterprise partner, FUJIFILM UK Limited (“Fujifilm UK”) and the One Dorset Pathology network. The introduction of Dynamyx at One Dorset Pathology represents the first of several new wins for Fujifilm UK using our software, and is a direct award from the PathLAKE digital and computational pathology consortium.
(PRNewsfoto/Fujifilm)
LEXINGTON, Mass. and IRVINE, Calif., May 12, 2021 /PRNewswire/ FUJIFILM Medical Systems U.S.A., Inc., a leading provider of biomarkers to assess the risk for the development of hepatocellular carcinoma (HCC), and Helio Health, an AI-driven healthcare company developing early cancer detection tests, today announced their collaboration to provide a blood-based assay that can help with the earlier detection of liver cancer. Through this relationship, Helio Health’s DNA methylation and biomarker-based blood test technology, recognized as the HelioLiver Test, will leverage Fujifilm’s 510(k)-cleared µTASWako® i30 Immunological test system for liver cancer biomarkers.
Liver cancer is the fastest growing and second deadliest cancer worldwide. According to the American Cancer Society, liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time. Studies show that early detection of liver cancer i
Agfa-Gevaert in Q1 2021: ongoing volume recovery, good performance by HealthCare IT and Digital Print & Chemicals - Regulated information
·
·
·
·
·
·
Positive free cash flow before extra pension funding
Mortsel (Belgium), May 11, 2021 - Agfa-Gevaert today commented on its results in the first quarter of 2021. In the seasonally weaker first quarter, the growth engines in the HealthCare IT and Digital Print & Chemicals divisions reported solid margin performances, which were offset by volume declines for some of our traditional products, as well as inflationary pressure. The Radiology Solutions division faced volume and price pressure for its medical film products due to the introduction of new centralized procurement practices in China. For the rest of the year, we expect the division s volumes and margins to recover substantially versus the exceptionally weak first quarter.
Examples of axial FLAIR sequences from studies within dataset A. From left to right: a patient with a likely normal brain; a patient presenting an intraparenchymal hemorrhage within the right temporal lobe; a patient presenting an acute infarct of the inferior division of the right middle cerebral artery; and a patient with known neurocysticercosis presenting a rounded cystic lesion in the left middle frontal gyrus. Image courtesy of Radiological Society of North America